Statistics from Altmetric.com
Current recommendations and guidelines for use of disease modifying drugs (DMDs) in relapsing-remitting multiple sclerosis refer to interferon β (IFNβ) and glatiramer acetate as injectables as well as the new orals teriflunomide, dimethyl fumarate (DMF) and also fingolimod, natalizumab and alemtuzumab. Several pivotal studies have demonstrated a short-term benefit for earlier treatment with DMDs on clinical and MRI activity but there are only limited data available from controlled studies on long-term clinical outcome including sustained accumulation of disability and conversion to secondary progression. Therapeutic decision-making in clinical practice is at risk to be influenced by patients’ needs for high tolerability and convenience of DMDs. Recently, reports on unexpected side effects of the new orals including single case reports of progressive …
Competing interests The author has received honoraria as a speaker and consultant from BIOGEN Inc, Genzyme, Merck Serono, Novartis and Teva in the last two years. He was involved as an investigator in clinical MS studies sponsored by BIOGEN, Merck Serono, Novartis, and Teva.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.